ResMed Releases New Mirage™ SoftGel Nasal Mask with Exclusive ConvertAble™ Series

San Diego - November 3, 2009

ResMed Corp. (NYSE: RMD) today released the new Mirage™ SoftGel nasal mask, the latest in its line of market-leading nasal interfaces for use in the treatment of sleep apnea.

The SoftGel is designed to offer exceptional comfort and versatility for patients and healthcare providers. As part of ResMed’s new exclusive ConvertAble™ Series, the SoftGel features an interchangeable frame which is also compatible with the high-performance Mirage Activa™ LT, allowing patients and clinicians greater freedom of choice with less hassle and inventory.

“ResMed’s SoftGel is an important component of our new ConvertAble Series and a strong addition to our mask portfolio as a whole. We believe the versatility of this product platform will not only help our customers improve patient compliance and engagement by offering more choice and comfort, but will also support business efficiency and cost savings by helping to achieve more successful titrations and reducing the need for costly swap-outs and callbacks,” stated JC Kyrillos, Senior Vice President of Sales, Marketing and Clinical Education, Americas.

Already, patients have indicated a strong preference for the SoftGel over other nasal gel masks. In market research trials, eight out of ten patients rated the SoftGel as more comfortable and durable than competitive masks. Additionally, three out of four patients rated their overall quality of sleep better with the SoftGel. The SoftGel provides a soft touch with strong stability for a comfortable, effective seal. Its unique DoubleGel™ cushion includes a blue gel layer for strong support and a clear gel layer that gently conforms to individual facial contours, making it easy, quick and intuitive to fit. It also features ResMed’s classic MicroFit dial, so patients can adjust their frame easily for added control and customization. Additionally, an array of special vents diffuses air away from the patient and their bed partner for ultra-quiet therapy that won’t disrupt their sleep.

The SoftGel incorporates a number of additional special features that enhance convenience for patients, including: Set-and-Forget headgear clips for easy attachment and removal; a 360° rotating elbow to accommodate multiple sleeping positions; and a comprehensive user support package with a travel bag and user guide.

Clinicians and HMEs will enjoy numerous benefits from the SoftGel mask. The interchangeable and shared components with the Activa LT will promote inventory efficiencies and cost savings, making it easier to replace one mask with the other if necessary. The durability and quality of the SoftGel will ensure consistent performance, resulting in fewer patient callbacks. Intuitive fitting features will reduce staff training and patient fitting time, and will help promote early therapy acceptance among patients with a comfortable, first-time fit. “With the SoftGel, we wanted to provide a high-performance nasal gel option with the renowned quality and durability of a ResMed mask,” added Kyrillos. “This new product answers the market need for flexible options in the gel mask category.”

For more information about the Mirage SoftGel, the ConvertAble Series or other ResMed products, contact ResMed Customer Service at (800) 424-0737, or visit www.resmed.com.

About ResMed

ResMed is a leading developer, manufacturer, and distributor of medical equipment for treating, diagnosing, and managing sleep disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com. Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company's Web  site.